.Kaufmann, P., Pariser, A. R. & Austin, C. Coming from medical discovery to procedures for unusual diseasesu00e2 $" the sight from the National Facility for Advancing Translational Sciencesu00e2 $" Workplace of Rare Diseases Research. Orphanet J. Rare Dis. 13, 196 (2018 ). Articleu00c2.PubMedu00c2.Google Scholaru00c2.Crooke, S. T. A phone call to upper arms against ultra-rare illness. Nat. Biotechnol. 39, 671u00e2 $ "677 (2021 ). Articleu00c2.CASu00c2.PubMedu00c2.Google.com Scholaru00c2.Vockley, J. et al. The developing part of health care geneticists in the era of genetics therapy: a seriousness to ready. Genet. Med. 25, 100022 (2023 ). Articleu00c2.CASu00c2.PubMedu00c2.Google.com Scholaru00c2.Kim, J. et al. Patient-customized oligonucleotide treatment for a rare genetic illness. N. Engl. J. Med. 381, 1644u00e2 $ "1652 (2019 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.Kim, J. et al. A structure for individualized splice-switching oligonucleotide treatment. Character 619, 828u00e2 $ "836 (2023 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.Lima, W. F. et al. Individual RNase H1 discriminates between refined variations in the design of the heteroduplex substratum. Mol. Pharmacol. 71, 83u00e2 $ "91 (2007 ). Articleu00c2.CASu00c2.PubMedu00c2.Google.com Scholaru00c2.Crooke, S. T., Cook, B. F., Crooke, R. M. & Liang, X.-H. Antisense technology: an overview and syllabus. Nat. Rev. Medication Discov. 20, 427u00e2 $ "453 (2021 ). Articleu00c2.CASu00c2.PubMedu00c2.Google.com Scholaru00c2.Lee, J.-R. et cetera. De novo anomalies in the electric motor domain name of KIF1A trigger cognitive problems, abnormal paraparesis, axonal neuropathy, and cerebellar atrophy. Hum. Mutat. 36, 69u00e2 $ "78 (2015 ). Articleu00c2.CASu00c2.PubMedu00c2.Google.com Scholaru00c2.Boyle, L. et al. Genotype as well as problems in microtubule-based motility connect with medical seriousness in KIF1A-associated neurological problem. HGG Adv. 2, 100026 (2021 ). CASu00c2.PubMedu00c2.Google Scholaru00c2.Kondo, M., Takei, Y. & Hirokawa, N. Motor protein KIF1A is vital for hippocampal synaptogenesis and also learning augmentation in an enriched atmosphere. Nerve cell 73, 743u00e2 $ "757 (2012 ). Articleu00c2.CASu00c2.PubMedu00c2.Google.com Scholaru00c2.Guo, Y. et al. An uncommon KIF1A missense anomaly enhances synaptic feature as well as boosts seizure task. Face. Genet. 11, 61 (2020 ). Articleu00c2.CASu00c2.PubMedu00c2.PubMed Centralu00c2.Google Scholaru00c2.Kaur, S. et cetera. Expansion of the phenotypic sphere of de novo missense alternatives in kinesin loved one 1A (KIF1A). Hum. Mutat. 41, 1761u00e2 $ "1774 (2020 ). Articleu00c2.CASu00c2.PubMedu00c2.PubMed Centralu00c2.Google Scholaru00c2.Canivez, G. L. & McGill, R. J. Variable design of the Differential Potential Scales-Second Version: exploratory and also hierarchical factor evaluations with the core subtests. Psychol. Assess. 28, 1475u00e2 $ "1488 (2016 ). Articleu00c2.PubMedu00c2.Google.com Scholaru00c2.Epstein, A. et cetera. Material verification of the lifestyle inventoryu00e2 $" disability. Child Care Wellness Dev. 45, 654u00e2 $ "659 (2019 ). Articleu00c2.PubMedu00c2.Google Scholaru00c2.Lek, M. et cetera. Evaluation of protein-coding hereditary variety in 60,706 humans. Attributes 536, 285u00e2 $ "291 (2016 ). Articleu00c2.CASu00c2.PubMedu00c2.Google Scholaru00c2.IND Submissions for Individualized Antisense Oligonucleotide Medication Products for Significantly Debilitating or Serious Ailments: Medical Suggestions (US Food and Drug Administration, 2022) https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ind-submissions-individualized-antisense-oligonucleotide-drug-products-severely-debilitating-or-lifeIND Articles for Customized Antisense Oligonucleotide Medicine Products: Managerial and Step-by-step Recommendations Advice for Sponsor-Investigators (United States Fda, 2021) https://www.fda.gov/regulatory-information/search-fda-guidance-documents/ind-submissions-individualized-antisense-oligonucleotide-drug-products-administrative-and-proceduralInvestigational New Medicine Request Submittings for Individualized Antisense Oligonucleotide Medicine Products for Severely Devastating or Life-Threatening Diseases: Chemistry, Manufacturing, and Controls Recommendations, Advice for Sponsor-Investigators (United States Food and Drug Administration, 2022) https://www.fda.gov/regulatory-information/search-fda-guidance-documents/investigational-new-drug-application-submissions-individualized-antisense-oligonucleotide-drugNonclinical Screening of Individualized Antisense Oligonucleotide Medicine Products for Badly Devastating or even Life-Threatening Diseases Support for Sponsor-Investigators (United States Fda, 2021) https://www.fda.gov/regulatory-information/search-fda-guidance-documents/nonclinical-testing-individualized-antisense-oligonucleotide-drug-products-severely-debilitating-or.